Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01435915
Recruitment Status : Completed
First Posted : September 19, 2011
Last Update Posted : May 18, 2018
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to investigate the pharmacokinetic profile of ropinirole PR after single and multiple doses of the PR-formulation. It will also investigate the safety and tolerability of ropinirole PR after single and multiple doses of PR-formulation.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: Ropinirole Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects
Actual Study Start Date : June 28, 2010
Actual Primary Completion Date : August 5, 2010
Actual Study Completion Date : August 5, 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Subjects receiving ropinirole
Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
Drug: Ropinirole

Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.

Single and repeat dose treatment periods will be separated by 7 days of washout period.

Primary Outcome Measures :
  1. Profile of Pharmacokinetics [ Time Frame: predose,1,2,3,4,6,8,10,12,14,16,18,20,22,24,36,48,72, 96,120,144,168 hours post-dose ]
    Cmax, AUC (0-24), AUC(0-inf)

  2. Profile of Pharmacokinetics [ Time Frame: predose,1,2,3,4,6,8,10,12,14,16,18,20,22,24 hours after last repeated dosing ]
    Css_max, Css_min and AUCss

Secondary Outcome Measures :
  1. Profile of Pharmacokinetics [ Time Frame: pre-dose,1,2,3,4,6,8,10,12,14,16,18,20,22, 24,36,48,72,96,120,144,168hours post-dose ]
    Tmax, T1/2, Kel

  2. Composition of Pharmacokinetics [ Time Frame: predose,1,2,3,4,6,8,10,12,14,16,18,20,22,24 hours after last repeated dosing ]
    Tmax, Css_av, DF,accumulation ratios (Ro and Rs)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy adult men and women between 18 and 45 years of age, inclusive.
  2. Body weight >=50Kg.
  3. Body Mass Index (BMI) 19 - 24 kg/m2.
  4. No abnormality on clinical examination.
  5. No abnormality revealed by the clinical chemistry or haematology examination at the pre-study medical examination.
  6. A normal 12-lead ECG at the pre-study screening.
  7. Normal systolic (100-140mmHg) and diastolic (<90mmHg) blood pressure at pre-study screening.
  8. Written informed consent prior to admission to the study.

Exclusion Criteria:

  1. Any clinically relevant abnormality identified on the screening history and physical or laboratory examination significant cardiovascular, neurological, psychiatric, haematological or renal abnormalities.
  2. Definite or suspected personal history or family history of adverse reactions or hypersensitivity to the study drug or to drugs with a similar chemical structure.
  3. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  4. The subject has received prescribed medication within 7 days prior to the first dosing day, which in the opinion of the principal medical investigator interfered with the study procedures or compromised safety.
  5. The subject has received over-the-counter (OTC) medicine within 48 hours prior to the first study day. Subjects who took OTC medication could still be entered into the study, if, in the opinion of the principal/co-investigator, the medication received did not interfere with the study procedures or compromised safety of the subjects.
  6. Abuse of alcohol, defined as an average weekly intake of greater than 21 units or an average daily intake of greater than three units. One unit is equivalent to half a pint of beer, one measure of spirits or one glass of wine.
  7. Positive screen for addictive drugs and tobacco.
  8. Participation in a trial with any drug within the 1 month before the start of the study.
  9. Either blood donation within the previous 3 months, or donation of a quantity of blood within the previous 12 months that would result in the subject having donated more than 1,500mL blood in a period from 12 months before this study up to and including the end of the study.
  10. Positive pre-study screening result for hepatitis B antigen, hepatitis C antibody and HIV-1/2 antibodies.
  11. Pregnancy and/or lactation;
  12. Female subjects of childbearing potential who are intending to become pregnant and/or are not willing to avoid pregnancy by means of barrier contraception methods (i.e. condoms or IUD) during the study from 5 days prior to screening or in the 3 months following the study.
  13. Female subjects with positive serum hCG test result at screening or on Days 1 of both study phases with positive urine HCG test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01435915

GSK Investigational Site
Beijing, China, 100032
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline

Additional Information:
Responsible Party: GlaxoSmithKline Identifier: NCT01435915     History of Changes
Other Study ID Numbers: 112558
First Posted: September 19, 2011    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs